Phathom Pharmaceuticals Inc. has announced a significant update from the U.S. Food and Drug Administration (FDA) regarding its gastrointestinal treatment, VOQUEZNA® (vonoprazan) tablets. The FDA has corrected its Orange Book listing to accurately reflect a full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA, effective through May 3, 2032. This update affirms the long-term commercial potential of the product as a first-in-class treatment. The exclusivity ensures that VOQUEZNA remains protected from generic competition in the U.S., solidifying its market position. No other organizations are involved in this regulatory exclusivity update.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。